Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Jens J. Holst, Mette M. Rosenkilde
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 8, pp. e2710-e2716
Open Access | Times Cited: 146

Showing 1-25 of 146 citing articles:

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Stefano Del Prato, Steven E. Kahn, Imre Pávó, et al.
The Lancet (2021) Vol. 398, Iss. 10313, pp. 1811-1824
Closed Access | Times Cited: 434
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
Naveed Sattar, Darren K. McGuire, Imre Pávó, et al.
Nature Medicine (2022) Vol. 28, Iss. 3, pp. 591-598
Open Access | Times Cited: 239
Child and adolescent obesity
Natalie B. Lister, Louise A. Baur, Janine F. Felix, et al.
Nature Reviews Disease Primers (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 234
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio, Daniel J. Drucker
Molecular Metabolism (2020) Vol. 46, pp. 101090-101090
Open Access | Times Cited: 220
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
Qian Zhang, Tenagne D. Challa, Robert Augustin, et al.
Cell Metabolism (2021) Vol. 33, Iss. 4, pp. 833-844.e5
Open Access | Times Cited: 195
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Piotr Mróz, Brian Finan, Vasily M. Gelfanov, et al.
Molecular Metabolism (2018) Vol. 20, pp. 51-62
Open Access | Times Cited: 175
Role of the gut–brain axis in energy and glucose metabolism
Hallie Wachsmuth, Savanna N. Weninger, Frank A. Duca
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 4, pp. 377-392
Open Access | Times Cited: 130
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan, Seun Akindehin, Camila E. Orsso, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 104
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Patrick J. Knerr, Stephanie A. Mowery, Jonathan D. Douros, et al.
Molecular Metabolism (2022) Vol. 63, pp. 101533-101533
Open Access | Times Cited: 86
GLP-1 and GIP receptor signaling in beta cells – A review of receptor interactions and co-stimulation
Ashok Mayendraraj, Mette M. Rosenkilde, Lærke S. Gasbjerg
Peptides (2022) Vol. 151, pp. 170749-170749
Open Access | Times Cited: 82
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Ania M. Jastreboff, Robert F. Kushner
Annual Review of Medicine (2023) Vol. 74, Iss. 1, pp. 125-139
Open Access | Times Cited: 80
Incretin hormones and type 2 diabetes
Michael A. Nauck, Timo D. Müller
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1780-1795
Open Access | Times Cited: 80
An update on peptide-based therapies for type 2 diabetes and obesity
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2023) Vol. 161, pp. 170939-170939
Open Access | Times Cited: 71
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders
Thian‐Sze Wong, Guangzhi Li, Shiliang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 62
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Rachel Sinha, Dimitris Papamargaritis, Jack A. Sargeant, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 1, pp. 25-45
Open Access | Times Cited: 61
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Rula Bany Bakar, Frank Reimann, Fiona M. Gribble
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 784-796
Closed Access | Times Cited: 59
Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents
Jingqian Su, Yingsheng Luo, Shan Hu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13381-13381
Open Access | Times Cited: 46
Targeting the incretin system in obesity and type 2 diabetes mellitus
Saleem Ansari, Bernard Khoo, Tricia Tan
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 8, pp. 447-459
Closed Access | Times Cited: 31
Transforming obesity: The advancement of multi-receptor drugs
Christine M. Kusminski, Diego Pérez–Tilve, Timo D. Müller, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3829-3853
Closed Access | Times Cited: 24
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
Areesha Moiz, Kristian B. Filion, Helia Toutounchi, et al.
Annals of Internal Medicine (2025) Vol. 178, Iss. 2, pp. 199-217
Closed Access | Times Cited: 7
Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation
Areesha Moiz, Kristian B. Filion, Michael A. Tsoukas, et al.
The American Journal of Medicine (2025)
Open Access | Times Cited: 2
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 2
Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
Aaron Novikoff, Shannon O’Brien, Miriam Bernecker, et al.
Molecular Metabolism (2021) Vol. 49, pp. 101181-101181
Open Access | Times Cited: 61
Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges
Núria Vilarrasa, Patricia San José, Miguel A. Rubio, et al.
Diabetes Metabolic Syndrome and Obesity (2021) Vol. Volume 14, pp. 2807-2827
Open Access | Times Cited: 60
Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
Harold Bays, Angela Fitch, Sandra Christensen, et al.
Obesity Pillars (2022) Vol. 2, pp. 100018-100018
Open Access | Times Cited: 47
Page 1 - Next Page

Scroll to top